Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones.

Administration of carbamazepine (CBZ) causes hypersensitivity reactions clinically characterized by skin involvement, eosinophilia, and systemic symptoms. These reactions have an immune etiology; however, the role of T cells is not well defined. The aim of this study was to characterize the specificity, phenotype, and cytokine profile of CBZ-specific T cells derived from hypersensitive individuals. Proliferation of blood lymphocytes was measured using the lymphocyte transformation test. CBZ-specific T cell clones were generated by serial dilution and characterized in terms of their cluster of differentiation and T cell receptor V beta phenotype. Proliferation, cytotoxicity, and cytokine secretion were measured by [(3)H]thymidine incorporation, (51)Cr release, and enzyme-linked immunosorbent assay, respectively. HLA blocking antibodies were used to study the involvement of antigen-presenting cells. The specificity of the drug T cell receptor interaction was studied using CBZ metabolites and other structurally related compounds. Lymphocytes from hypersensitive patients (stimulation index: 32.1 +/- 24.2 [10 microg ml(-1)]) but not control patients (stimulation index: 1.2 +/- 0.4 [10 microg ml(-1)]) proliferated upon stimulation with CBZ. Of 44 CBZ-specific T cell clones generated, 10 were selected for further analysis. All 10 clones were either CD4+ or CD4+/CD8+, expressed the alpha beta T cell receptor, secreted IFN-gamma, and were cytotoxic. T-cell recognition of CBZ was dependent on the presence of HLA class II (DR/DQ)-matched antigen-presenting cells. The T cell receptor of certain clones could accommodate some CBZ metabolites, but no cross-reactivity was seen with other anticonvulsants or structural analogs. These studies characterize drug-specific T cells in CBZ-hypersensitive patients that are phenotypically different from T cells involved in other serious cutaneous adverse drug reactions.

[1]  J. Zakrzewska,et al.  In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. , 1988, The Journal of allergy and clinical immunology.

[2]  B. K. Park,et al.  Bioactivation of carbamazepine in the rat in vivo. Evidence for the formation of reactive arene oxide(s). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[3]  J. Muglia,et al.  Anticonvulsant hypersensitivity syndrome. , 1995, Archives of internal medicine.

[4]  Martine Bagot,et al.  Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. , 2002, The Journal of investigative dermatology.

[5]  H. Merk,et al.  CD8+ dermal T cells from a sulphamethoxazole‐induced bullous exanthem proliferate in response to drug‐modified liver microsomes , 1995, The British journal of dermatology.

[6]  M. Britschgi,et al.  Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions , 2002, American journal of clinical dermatology.

[7]  A. Frigerio,et al.  Iminostilbene—a metabolite of carbamazepine isolated from rat urine , 1973, The Journal of pharmacy and pharmacology.

[8]  K. Frutig,et al.  T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. , 2000, The Journal of investigative dermatology.

[9]  B. Chapuis,et al.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. , 1968, Immunology.

[10]  W. Pichler,et al.  Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones. , 2001, International immunology.

[11]  N. Kitteringham,et al.  Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. , 1989, British journal of clinical pharmacology.

[12]  M. Blanca,et al.  Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. , 2000, The Journal of allergy and clinical immunology.

[13]  S. Valitutti,et al.  HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. , 1998, The Journal of clinical investigation.

[14]  W. Pichler,et al.  Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. , 2000, The Journal of allergy and clinical immunology.

[15]  M. Britschgi,et al.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis. , 2001, The Journal of clinical investigation.

[16]  C. Brander,et al.  Characterization of lidocaine-specific T cells. , 1997, Journal of immunology.

[17]  W. Pichler,et al.  The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  A. Ohta,et al.  Indispensable Role for TNF-α and IFN-γ at the Effector Phase of Liver Injury Mediated by Th1 Cells Specific to Hepatitis B Virus Surface Antigen1 , 2000, The Journal of Immunology.

[19]  J. Leeder.  Mechanisms of Idiosyncratic Hypersensitivity Reactions to Antiepileptic Drugs , 1998, Epilepsia.

[20]  A. Kappeler,et al.  T cell involvement in cutaneous drug eruptions , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  J. Nakayama,et al.  Interferon-gamma production in the peripheral lymphocytes of a patient with carbamazepine hypersensitivity syndrome. , 2000, Acta dermato-venereologica.

[22]  M. Pirmohamed,et al.  TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients , 2001, Neurology.

[23]  Pichler,et al.  T‐cell‐mediated cytotoxicity against keratinocytes in sulfamethoxazol‐induced skin reaction , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  R. Stern,et al.  Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study , 1997, Neurology.

[25]  D. Golan,et al.  Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. , 1995, Immunity.

[26]  W. Pichler,et al.  Degeneracy and additional alloreactivity of drug-specific human αβ+ T cell clones , 2001 .

[27]  M. Pirmohamed,et al.  Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. , 1994, Archives of dermatology.

[28]  D. Kemeny,et al.  Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens , 1996, Immunology.

[29]  W. Pichler,et al.  High IL-5 production by human drug-specific T cell clones. , 1997, International archives of allergy and immunology.

[30]  Yoshimasa Tanaka,et al.  Direct presentation of nonpeptide prenyl pyrophosphate antigens to human γδ T cells , 1995 .

[31]  T. Tomson,et al.  Carbamazepine therapy in trigeminal neuralgia: clinical effects in relation to plasma concentration. , 1980, Archives of neurology.

[32]  J. Roujeau,et al.  Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. , 1992, Archives of dermatology.

[33]  R. Siliciano,et al.  Major histocompatibility complex independent T cell receptor-antigen interaction: functional analysis using fluorescein derivatives , 1991, The Journal of experimental medicine.

[34]  M. Pirmohamed,et al.  Characterization of the metabolites of carbamazepine in patient urine by liquid chromatography/mass spectrometry. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[35]  D. Basketter,et al.  Characterization of chemical allergens as a function of divergent cytokine secretion profiles induced in mice. , 1996, Toxicology and applied pharmacology.

[36]  R. Booy,et al.  Carbamazepine hypersensitivity and the use of lymphocyte proliferation responses , 1999, Developmental medicine and child neurology.

[37]  M. Karakaş,et al.  The anticonvulsant hypersensitivity syndrome , 2003, Journal of the European Academy of Dermatology and Venereology : JEADV.

[38]  J. Uetrecht,et al.  Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. , 1999, The Journal of pharmacology and experimental therapeutics.

[39]  M Pirmohamed,et al.  Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. , 1998, Chemical research in toxicology.

[40]  C. Brander,et al.  Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. , 1995, Journal of immunology.

[41]  A. Ohta,et al.  Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen. , 2000, Journal of immunology.

[42]  W. Pichler,et al.  Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. , 1997, The Journal of clinical investigation.

[43]  K. Frutig,et al.  Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. , 1999, Journal of immunology.